BDR is a niche player in today’s global arena. BDR is specialized in early identification, development and introduction of new fourth generation medicines for life threatening disease.

BDR with its unique strategy of multi-branding policy makes these medicines available across the globe at affordable prices. BDR has achieved success due to highly qualified professionals with the experience of serving the pharmaceutical industry for 30 years.

As the CMD of the company, I myself have a background of chemical engineering from the Mumbai University. The team at BDR also consists of the Technical Director having the qualification of Doctorate in Organic Chemistry, along with graduates who have completed their MS, MBBS, M.Pharm and MSc.

This irreplaceable Team adopts its strategies towards achieving its vision for the growth of this evolving organization. This is what differentiates us from the various giants in the Pharma field and has helped us to create our own unique identity and importance.

I have dedicated 10 years of my life since 1994 to 2004 for serving good quality generic for HIV/AIDS. Since 2004 during the promotion of BDR I have decided to focus mainly on Oncology Products and various therapeutic categories such as antibodies, neuropsychiatry, gynecology and fourth generation antibiotics and penam group.

Latest news

October 2013 BDR is participating at Frankfurt CPHI 2013 and kindly visit us at Hall No.4.0 Stand No. 40D01. CPHI Worldwide 2013 Messe Frankfurt, Germany from 22 – 24 October 2013
2011 BDR Pharma is awarded the best exporter GOLD Award by Pharmexcil of India.
October 2011 BDR pharma is participating in CPHI 2011 at Frankfurt, Germany from 25th to 27th of October 2011 and visit us at Stall No. 51 F 51
September 2011 BDR Pharma is working on many blockbusters in various therapy areas like : Oncology, Penem’s, Cardiology, Genecology etc..
August 2011 BDR pharma has launched Caspofungin Acetate 50 mg / 70 mg – First Generic player in the world after originator
April 2011 BDR pharma has launched Doripenem 250 mg / 500 mg* - Most successful penem in carbapenem group
05/08/2010 BDR pharma is participating in CPHI 2010 at Paris and visit us at Hall 5 A, Stand 5B 102.
20/05/2010 Foundation Day of BDR Lifesciences Pvt. Ltd.
04/01/2010 BDR Pharma has successfully launched high ended generic oncology molecules in India.